Company profile: Marengo Therapeutics
1.1 - Company Overview
Company description
- Provider of T cellβmodulating antibody platforms and therapeutics, including the STAR bi-functional molecule platform pairing anti-VΞ² antibodies with costimulatory signals for antigen-rich 'hot' tumors; the TriSTAR T cell engager for antigen-low 'cold' tumors; TCR-targeting antibodies; an antibody technology platform using genomics and TCR sequencing; and STAR0602, in Phase I/II (START-001) for advanced antigen-rich solid tumors.
Products and services
- STAR0602: A T cell activator that targets VΞ²6/10 T cells to enhance anti-tumor immune response and promote durable cancer cell clearance
- STAR Platform: A bi-functional molecule platform pairing anti-VΞ² antibodies with T cell costimulatory signals to activate defined T cell subsets in antigen-rich 'hot' tumors
- TriSTAR Platform: A T cell engager platform engineered to target and expand VΞ² T cells in antigen-low 'cold' tumors, enabling potent and durable anti-tumor activity
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Marengo Therapeutics
IGM Biosciences
HQ: United States
Website
- Description: Provider of a proprietary, clinical-stage IgM antibody platform developing engineered IgM therapeutics for cancer, autoimmune and inflammatory diseases. Pipeline includes imvotamab (CD20xCD3) for autoimmune diseases, aplitabart (DR5) for colorectal cancer, and IGM-2644 (CD38xCD3) for autoimmune diseases, all in early trials. Also offers an expanded access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full IGM Biosciences company profile β
JW Holdings
HQ: South Korea
Website
- Description: Provider of prescription drugs, over-the-counter drugs, and medical equipment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full JW Holdings company profile β
Xspray Pharma
HQ: Sweden
Website
- Description: Provider of improved and generic versions of marketed protein kinase inhibitors, using patented Hynap Technology to create amorphous formulations for faster post-patent entry. Portfolio includes Dasynoc (improved dasatinib for CML/ALL with lower dose, reduced absorption variability, and gastric acid suppressant compatibility), XS004 (dasatinib), and XS025 (cabozantinib for renal cell carcinoma and other cancers).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Xspray Pharma company profile β
LadRx
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics leveraging LADR (Linker Activated Drug Release) technology to bind anti-cancer molecules to albumin and release cytotoxic payloads at tumors, enabling higher doses with minimized off-target toxicity. Portfolio includes Aldoxorubicin, next-generation LADR-7, and Arimoclomol to amplify heat-shock proteins against protein misfolding, aggregation, and lysosomal dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full LadRx company profile β
Vaxess
HQ: United States
Website
- Description: Provider of needle-free vaccine and therapeutic delivery solutions, offering the MIMIX applicator with patch for skin-based administration and silk fibroin biomaterials that create stable, biocompatible delivery systems, with a focus on improving access to vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Vaxess company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Marengo Therapeutics
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Marengo Therapeutics
2.2 - Growth funds investing in similar companies to Marengo Therapeutics
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Marengo Therapeutics
4.2 - Public trading comparable groups for Marengo Therapeutics
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β